Objectives: The potential benefit from appropriate empirical antimicrobial therapy in patients with favourable prognosis at initial presentation with Gram-negative bloodstream infection (BSI) remains unclear. This retrospective cohort study examined the impact of inappropriate empirical antimicrobial therapy on hospital length of stay (HLOS) following Gram-negative BSI after stratification by predicted prognosis using the BSI mortality risk score (BSIMRS).
Introduction
Over 500 000 individuals develop bloodstream infections (BSI) annually in the USA, including nearly 250 000 Gram-negative BSI. 1, 2 The impact of inappropriate empirical antimicrobial therapy on mortality in patients with Gram-negative BSI has been previously examined. 3 -9 Most studies that included large numbers of patients with high acute severity of illness, major comorbidities and non-urinary source of infection have demonstrated increased mortality in patients who received inappropriate empirical antimicrobial therapy. 3 -5 However, survival benefit from appropriate empirical antimicrobial therapy was not demonstrated in studies that predominantly included non-critically ill patients or those with low inoculum infections such as urinary source of BSI. 6 -9 These observations were confirmed in a recent study that examined mortality in patients with Gram-negative BSI after stratification by predicted prognosis utilizing the BSI mortality risk score (BSIMRS). 10 The score included acute severity of illness, source of infection and major comorbidities as summarized in Table 1 . 11, 12 There was an association between inappropriate empirical antimicrobial therapy and mortality in patients with guarded prognosis (BSIMRS ≥5). However, survival difference was not demonstrated in patients with good prognosis at initial presentation (BSIMRS ,5).
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This leaves potential benefit from appropriate empirical antimicrobial therapy unclear in the latter group.
Moreover, inappropriate empirical antimicrobial therapy has been associated with increased hospital length of stay (HLOS) in patients with Gram-negative sepsis in previous studies. 13 To our knowledge, this association has not been demonstrated in patients with good predicted prognosis at initial presentation with Gram-negative BSI. This retrospective cohort study examined the association between inappropriate empirical antimicrobial therapy and HLOS in patients with Gram-negative BSI overall and after stratification by predicted prognosis using the BSIMRS.
Methods

Setting
The study was conducted at Palmetto Health Richland and Baptist Hospitals in Columbia, SC, USA. The two hospitals have a combined total of .1100 licensed beds and provide care in a wide variety of medical and surgical subspecialties for local residents of Richland County as well as regional referrals.
Ethics
The Institutional Review Board at Palmetto Health approved the study and waived informed consent.
Definitions
Gram-negative BSI was defined as the growth of any aerobic Gramnegative bacillus in a blood culture. Monomicrobial BSI was defined as the growth of only one species of microorganism in a blood culture and polymicrobial BSI was defined as the growth of more than one microorganism in a blood culture. 15 The primary source of BSI was defined according to the CDC criteria. 16 The site of infection acquisition was classified into community acquired, healthcare associated and nosocomial as previously defined. 17 HLOS was defined as time in days from collection of index blood culture to discharge from the hospital. 13, 14 Empirical antimicrobial therapy was defined as antimicrobial agents received within the first 48 h following collection of the index blood culture. Appropriateness of empirical antimicrobial therapy was based on dosing, route of administration and in vitro antimicrobial susceptibility testing results as previously defined. 10 Briefly, empirical antimicrobial therapy was considered appropriate if it met all of the following criteria: (i) the patient received at least the minimum recommended dose of an antimicrobial agent according to the medication package insert for creatinine clearance at the time of BSI; (ii) the empirical antimicrobial agent was administered via the intravenous route, with the exception of fluoroquinolones, which were considered appropriate if administered orally in haemodynamically stable patients due to relatively high oral bioavailability; and (iii) the bloodstream isolate was susceptible to the empirical antimicrobial agent based on in vitro antimicrobial susceptibility testing results using CLSI guidelines.
Case ascertainment
In this retrospective cohort study, all patients with BSI due to aerobic Gram-negative bacilli from 1 January 2010 to 31 December 2013 through microbiology laboratory databases at Palmetto Health were identified. Hospitalized patients ≥18 years old with first episodes of monomicrobial BSI due to Gram-negative bacilli were included in the study (n ¼ 830). Children (n ¼ 98), polymicrobial BSI (n ¼ 121) and recurrent episodes of BSI (n¼34) were excluded.
Statistical analysis
Kaplan -Meier analysis was used to examine HLOS following Gramnegative BSI. Patients were followed from time of collection of index blood culture until discharge from the hospital. This allowed censoring of patients who died prior to hospital discharge in order to avoid accounting for early death as a favourable outcome. Log-rank P value was used to assess the statistical significance of the difference in HLOS between patients who received appropriate and inappropriate empirical antimicrobial therapy. Cox proportional hazards regression was used to identify risk factors for remaining hospitalized. Age, sex, ethnicity, chronic comorbidities, site of infection acquisition, appropriateness of empirical antimicrobial therapy and the component variables as well as the BSIMRS were evaluated as potential risk factors for prolonged HLOS. In order to identify variables that were independently associated with HLOS, risk factors were included in a multivariate Cox model if the P value for a univariate association with HLOS was ≤0.10. In the multivariate Cox model, the components of the BSIMRS were not individually analysed; instead, the total score based on the individual components was analysed as a continuous variable. The proportional hazards assumption was evaluated by plotting the log integrated hazard versus time from the Kaplan-Meier method. HRs with 95% CIs were presented to demonstrate the strength of association between each risk factor and HLOS. Then, patients were stratified based on predicted prognosis at the time of diagnosis of Gram-negative BSI into good (BSIMRS ,5) and guarded prognosis (BSIMRS ≥5). These categories were predefined based on the discriminative ability of BSIMRS to predict the prognosis of patients with Gram-negative BSI in previous studies. 11, 12 Multivariate Cox proportional hazards regression was used to examine the impact of inappropriate empirical antimicrobial therapy on HLOS in each BSIMRS group after adjustments for risk factors for prolonged HLOS other than BSIMRS and appropriateness of empirical antimicrobial therapy, if any. Median HLOS based on appropriateness of empirical antimicrobial therapy in each BSIMRS group was obtained from the respective multivariate Cox model.
A secondary analysis was performed after stratification of patients by acute severity of illness as defined by admission to the ICU at the time of BSI. Multivariate Cox proportional hazards regression was used to examine the impact of inappropriate empirical antimicrobial therapy on HLOS in patients with Gram-negative BSI who were treated inside and outside the ICU.
JMP Pro (version 12.0, SAS Institute, Cary, NC, USA) was used for statistical analysis. The level of significance for statistical testing was defined as P,0.05 (two-sided) unless otherwise specified. Battle et al.
Results
During the 4 year study period, 830 unique patients with Gram-negative BSI were included. The demographic and clinical characteristics of the cohort are shown in Table 2 . Overall, the median age was 65 years and 448 (54%) were women. Escherichia coli (444; 53%) was the most common bloodstream isolate and the urinary tract (444; 53%) was the most common source of infection. The majority of cases were community acquired (344; 41%) or healthcare associated (316; 38%); the remaining 170 (20%) BSI were nosocomial. Only 72 (9%) patients received inappropriate empirical antimicrobial therapy in this cohort.
Overall, inappropriate empirical antimicrobial therapy was associated with prolonged HLOS following Gram-negative BSI in Kaplan -Meier analysis (log-rank P ¼ 0.004; Figure 1 ).
Risk factors for prolonged HLOS in unadjusted univariate analysis included male sex, end-stage renal disease, recent hospitalization, length of stay prior to BSI, BSIMRS and inappropriate empirical antimicrobial therapy (Table 3) .
After adjustments in multivariate analysis, length of stay prior to BSI, BSIMRS and inappropriate empirical antimicrobial therapy were independently associated with prolonged HLOS following (Figure 2) .
In a secondary analysis, the impact of inappropriate empirical antimicrobial therapy on HLOS was retained in both critically ill patients with Gram-negative BSI treated in the ICU (aHR ¼ 2.96, 95% CI ¼ 1.43 -7.17, P ¼ 0.002) and non-critically ill patients treated outside the ICU (aHR ¼ 1.44, 95% CI ¼ 1.06 -1.99, P ¼ 0.02).
Discussion
The study demonstrates an independent association between inappropriate empirical antimicrobial therapy and prolonged HLOS following Gram-negative BSI regardless of prognosis at initial presentation. This demonstrates benefit from appropriate empirical antimicrobial therapy in patients with good prognosis (BSIMRS ,5) and adds to the previously described survival benefit in those with guarded prognosis (BSIMRS ≥5) at initial presentation. 10 The association between inappropriate empirical antimicrobial therapy and prolonged HLOS in patients with guarded prognosis and critically ill ones treated in the ICU is consistent with the results of previous studies that have reported this observation in patients with Gram-negative sepsis. 13, 14 To our knowledge, this is the first study to demonstrate this association in patients with good predicted prognosis and non-critically ill patients with Gram-negative BSI.
Maximizing the benefit-to-risk ratio of antimicrobial therapy is of paramount importance for patients' quality of care. The risks of antimicrobial therapy such as Clostridium difficile infection, nephrotoxicity and induction of antimicrobial resistance have been previously summarized. 18 However, the benefits of appropriate empirical antimicrobial therapy remain imprecisely defined. 19 This has been attributed mostly to use of inconsistent methodologies in accounting for baseline clinical characteristics of patients. 20 The BSIMRS provides a useful tool for adjustments of baseline clinical characteristics as it encompasses predictors of mortality in patients with Gram-negative BSI: acute severity of illness, major comorbidities and source of infection. 11, 12 Utilization of the BSIMRS in the current study allowed examination of the benefits of appropriate empirical antimicrobial therapy even in patients with good prognosis. In prior studies, the predicted 28 day survival in non-critically ill patients without major comorbidities who have Gram-negative BSI secondary to urinary source (BSIMRS ,5) exceeded 95% overall and approached 99% in the absence of hypotension or respiratory failure as in patients with BSIMRS ,2.
11,12 Due to high survival rates in these patients with good predicted prognosis, a mortality difference based on appropriateness of empirical antimicrobial therapy was not previously established. 10 However, the association between inappropriate empirical antimicrobial therapy and prolonged hospitalization in patients with Gram-negative BSI and good predicted prognosis is conceivable. Receipt of inappropriate empirical antimicrobial therapy may lead to delayed clinical response to treatment in these patients such as persistence of fever or other symptoms until antimicrobial therapy is appropriately revised based on in vitro antimicrobial susceptibility testing results. The financial impact of prolonged hospitalization approaches $13000 of additional cost per patient based on recent estimates from the USA. 21 The current study utilized HLOS as a primary endpoint to maintain consistency with previous literature. 13, 14 It is conceivable that some patients may remain hospitalized following completion of antimicrobial therapy due to either complications of Gram-negative BSI such as respiratory, renal or other end organ failure or due to factors unrelated to infection. However, reporting median HLOS in the current study minimizes the impact of outliers on overall results. It would be interesting to define clinical failure criteria within 48-96 h following BSI that are associated with either mortality or prolonged HLOS in future studies. That would establish objective evidence-based criteria to examine the outcome of patients with Gram-negative BSI, particularly those with low predicted mortality. In addition, using standardized clinical failure criteria makes comparisons across different studies more practical. The current study demonstrates that the BSIMRS predicts HLOS in survivors of Gram-negative BSI in addition to predicting mortality as previously reported. 11, 12 Patients with high BSIMRS at initial presentation were at increased risk of remaining hospitalized compared with those with lower BSIMRS. It was also noted that most of the individual components of the BSIMRS were associated with prolonged HLOS. This emphasizes the importance of adjustments for major comorbidities, acute severity of illness and source of infection when examining outcomes of patients with Gram-negative BSI, including HLOS. Notably, demographic variables such as age and sex were not independently associated with HLOS in the current study. Male sex was associated with increased HLOS in univariate analysis, but not after adjustment for source of BSI among other variables in the multivariate model. This was likely due to the higher proportion of men with a non-urinary source of Gram-negative BSI as compared with women.
The demonstration of benefit from appropriate empirical antimicrobial therapy in patients with Gram-negative BSI regardless of initial prognosis is not a justification for nonstratified use of broad-spectrum empirical antimicrobial therapy. Rather, it is an incentive for healthcare providers to use currently existing tools to predict microbiology and in vitro antimicrobial susceptibility testing results based on site of infection acquisition, prior exposure to antimicrobial agents and other clinical risk factors for antimicrobial resistance. 22 -24 Development of institutional and regional management guidelines based on local risk factors may be useful in reducing the burden of Gram-negative BSI by improving the appropriateness of empirical antimicrobial therapy. 1 Higher benefit from appropriate empirical antimicrobial therapy (lower mortality and shorter HLOS) in patients with BSIMRS ≥5 as compared with those with BSIMRS ,5 (shorter HLOS only) justifies using different thresholds for selection of broad-spectrum therapy based on risk factors for antimicrobial resistance and predicted prognosis at initial presentation.
In summary, there is benefit from appropriate empirical antimicrobial therapy in patients with good and guarded prognosis at initial presentation of Gram-negative BSI. Appropriate selection of empirical antimicrobial therapy is associated with reduction in HLOS in patients with Gram-negative BSI.
